Whole genome data analysis method for capturing circulating tumor cells based on physics
Through the genome-wide analysis method combined with CTCBIOPSY system and laser microcutting technology, the false positive and false negative problems of circulating tumor cell detection are solved, achieving higher detection specificity and early diagnosis accuracy.
Patent Information
- Application Number
- CN202411121056.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
Smart Images

Figure CN119028434A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of bioinformatics, and in particular relates to a whole genome data analysis method based on physics-based capture of circulating tumor cells. Background Art
[0002] Circulating tumor cells (CTCs) are tumor cells that fall off from primary tumors or metastatic tumors and enter the blood circulation. After entering the blood, most of these tumor cells are cleared by the body's immune mechanism or fluid shear force and other factors. The few cells that escape and remain can be implanted in distant places and develop into metastatic tumors, significantly increasing the risk of death in patients with malignant tumors. At present, circulating tumor cells are one of the main liquid biopsy markers, and conventional CTC counts play an important role in the early diagnosis of tumors, efficacy evaluation, prognosis prediction, and recurrence and metastasis monitoring. With the deepening of tumor research, the application direction of CTC has been continuously expanded, and its downstream analysis has also attracted much attention, such as CTC molecular typing, genetic testing, cell culture, etc. These studies can provide more abundant tumor information in addition to clinical counting, and are of high value in guiding patient medication, tumor resistance and metastasis mechanism research.
[0003] There are many methods for separating and identifying circulating tumor cells on the market. Separation methods mainly include two categories based on immunological principles and physical principles. Immunological methods refer to the capture of tumor cells based on cell surface markers (such as CK, EpCAM, Vimentin, CD45, etc.), including positive enrichment and negative enrichment. Such methods have high specificity, but due to the high rarity and heterogeneity of CTCs, and epithelial-mesenchymal transition (EMT) occurs in the blood circulation, so positive enrichment may miss some EMT-transformed tumor cells; negative enrichment achieves the purpose of tumor cell enrichment by filtering out white blood cells, and there are many operation steps, and cell loss and enrichment purity need to be considered. Physical methods capture tumor cells based on the physical properties of cells (cell size filtration, gradient density centrifugation, cell charge differences, etc.), do not rely on cell markers, and are applicable to most solid tumors. Identification methods mainly include cell morphology identification, immunofluorescence identification, FISH identification, aptamer PCR, etc. However, due to the high heterogeneity of tumors, the above conventional detection methods may have false positive or false negative problems, which to a certain extent limits the clinical application of CTCs.
[0004] Next Generation Sequencing (NGS) is a high-throughput sequencing method that can detect various genetic variation information including point mutations, insertions and deletions, copy number variations, microsatellite instability, etc. Among them, copy number variation (CNV) is caused by genome rearrangement and is a form of structural variation. It analyzes the overall chromosome variation and is cheaper than deep gene panel testing. Studies have found that CNV is almost universal in malignant tumors. Tumors of the same type have similar CNV patterns, while tumors of different types have their own CNV patterns. Therefore, CNV detection can be used as a marker for the diagnosis of malignant tumors. Summary of the invention
[0005] In view of this, the present invention aims to develop a method for obtaining, sequencing and analyzing circulating tumor cells, so as to overcome the application limitations of circulating tumor cell counting detection and the problem that patients with malignant tumors cannot obtain tissues in real time for benign and malignant differentiation, as well as the problem that existing CTC detection methods may have false positives and false negatives, further improve the specificity of tumor detection, and provide more accurate tumor information for clinicians.
[0006] The technical solution of the present invention is as follows: The present invention provides a method for analyzing whole genome data of circulating tumor cells captured based on physics, which comprises the following steps: S1. CTCBIOPSY system is used to separate circulating tumor cells in enriched blood samples based on cell physical properties, and target cells are picked based on cell morphology and by laser microdissection. S2, perform whole genome sequencing on target cells; S3. Analyze the sequencing data to obtain genetic variation information of target cells.
[0007] In the method of the present invention, circulating tumor cells include, but are not limited to, circulating tumor cells in blood samples of patients with lung cancer, gastric cancer, colon adenocarcinoma, glioma and breast cancer.
[0008] Preferably, in the above method, the pore size of the filter membrane used in the CTCBIOPSY system is 8 μm.
[0009] Preferably, in the above method, step S1 comprises: S11. Obtain peripheral blood from the patient and use the CTCBIOPSY system to separate and enrich circulating tumor cells; S12, taking out the filter membrane in the CTCBIOPSY system, and using Wright-Giemsa staining solution to stain cells and prepare slides; S13, reading the slides and picking target cells to be tested by laser microdissection according to cell morphology, wherein the target cell picking criteria at least meet any of the following conditions: ① Abnormal karyotype, such as lobed or mulberry-shaped nuclei, can be judged by comparing the morphology of surrounding blood cells; ② The nuclear-cytoplasmic ratio is greater than 0.8; ③ The cell diameter (long end) is greater than 15 μm; ④ The nucleus is deeply stained and unevenly stained, mainly because the tumor cells have increased chromatin and coarsened particles; ⑤ The nuclear membrane thickens, becomes concave or wrinkled, and becomes irregular; ⑥ Giant nucleoli or abnormal nuclear division appear.
[0010] More preferably, if the target cell meets at least 4 conditions, it can be confirmed as CTC, if the target cell has condition ⑥ and meets the other two conditions at the same time, it can be confirmed as CTC, and if the target cell only has condition ⑥ or meets any other three conditions, it can be confirmed as suspected CTC. Among them, a cell cluster composed of 3 or more CTCs gathered together is confirmed as circulating tumor microthrombus (CTM).
[0011] More preferably, step S11 specifically comprises: fixing and diluting the peripheral blood sample with paraformaldehyde and physiological saline; rinsing the cell filter in the CTCBIOPSY system with 75% alcohol and physiological saline, and then separating and enriching the peripheral blood sample.
[0012] More preferably, step S12 specifically includes: taking out the filter membrane in the cell filter and sticking it on a glass slide, first staining it with eosin, and then staining it with methylene blue.
[0013] Preferably, in the above method, step S2 specifically comprises: firstly using a MALBAC whole genome amplification kit to amplify the target cell genome, and then using second-generation sequencing technology to perform low-depth whole genome sequencing.
[0014] In the above method, step S3 obtains the target cell genetic variation information including but not limited to single nucleotide variations (SNVs), insertion and deletion mutations (Indels) and CNV, etc. Preferably, the target cell genetic variation information is CNV, and step S3 specifically includes the following process: S31, perform quality control on sequencing data; S32. Use bowtie2 to align the reads obtained after quality control with the reference genome, use samtools to calculate the base coverage value, distinguish different chromosomes and divide the bin units according to the length of 200k, calculate the average coverage value of the bin, calculate the Z-score value according to formulas (1) and (2), and then use the Z-score value to perform CNV map analysis; Among them, formula (1) and formula (2) are specifically as follows: , , In the formula, Coverage raw Coverage refers to the original coverage obtained by sequencing. controls, raw refers to the original coverage of the experimental control sample, V tumor refers to the normalized sequencing coverage of tumor samples, V control is the normalized sequencing coverage of the control sample.
[0015] More preferably, the quality control conditions in step S31 are: Filter out reads containing adapter sequences; When the number of undetected bases in a single-end sequencing read exceeds 5% of the length of the read, the read and the reads that form a paired-end pair with the read are filtered out; When the number of low-quality bases in a single-end sequencing read exceeds 20% of the length of the read, the read and the reads that form a paired-end pair with the read are filtered out.
[0016] More preferably, the reference genome in step S32 is the human genome reference sequence GRCh38.
[0017] Compared with the prior art, the beneficial effects of the present invention are: The method of the present invention utilizes the CTCBIOPSY system to separate and enrich CTCs based on cell size, and uses cell morphology to pick target cells. This method does not rely on tumor cell surface markers, has a better effect on separating circulating tumor cell microemboli, and has the advantages of simple operation and high enrichment efficiency. It can also reduce damage to CTCs to achieve the purpose of maintaining the integrity of CTC cells, facilitating subsequent whole genome sequencing of target cells.
[0018] The method of the present invention is applicable to most solid tumors and is compatible with a variety of CTC downstream sequencing and analysis methods, including but not limited to CTC-CNV detection, CTC-panel detection, CTC-WES detection, and CTC whole genome detection. For example, in some embodiments of the present invention, CNV analysis is performed on isolated CTCs or suspected CTCs, and more accurate tumor information can be obtained through CTC whole genome low-depth sequencing data analysis, which is particularly important for early diagnosis and identification of tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1Schematic diagram of the structure of the cell filter used in the embodiment of the present invention.
[0020] Figure 2 The figure is a schematic diagram of the cell morphology of peripheral blood circulating tumor cells under an optical microscope in the method of the present invention.
[0021] Figure 3 The figure is a schematic diagram of the cutting field of peripheral blood circulating tumor cells under a laser microscope in the method of the present invention.
[0022] Figure 4 This is the gene copy number map of circulating tumor cells in the blood of tumor patients obtained in Example 2 of the present invention.
[0023] Figure 5 This is a comparison of CNV differences based on Z-score value analysis after low-depth whole-genome sequencing of CTC samples of healthy people and different cancer types in Example 3 of the present invention. DETAILED DESCRIPTION
[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. The term "comprises" and any variations thereof in the specification and claims of the present invention are intended to cover non-exclusive inclusions.
[0025] The technical solution of the present invention will be described clearly and completely below in conjunction with specific embodiments. It should be understood that the embodiments described herein are only used to illustrate and explain the present invention and are not used to limit the present invention.
[0026] If no specific techniques or conditions are specified in the following examples, the procedures are carried out in accordance with the techniques or conditions described in the literature in the art or in accordance with the product instructions; if no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0027] Example 1 This example provides a method for analyzing whole genome data of circulating tumor cells captured based on physics, including the following steps: (1) Collect 5 mL of blood from patients with malignant tumors.
[0028] Use K2-EDTA anticoagulant blood collection tubes to collect venous blood samples. After collection, gently invert the blood collection tubes to mix them. It is worth noting that if the patient is undergoing other blood collection projects at the same time, the CTC blood sample should be collected after the other projects are completed. If the subject does not have other blood collection projects, the first 1mL of venous blood needs to be discarded when collecting blood before collecting the CTC blood sample.
[0029] The samples do not need to be refrigerated, they can be stored at room temperature, and they need to be pre-processed within 2 hours after collection. If the test cannot be performed within 2 hours, please store them vertically in a 4°C refrigerator for no more than 24 hours. Samples stored in a 4°C refrigerator should be rewarmed at room temperature for at least 30 minutes before processing.
[0030] (2) Isolation and enrichment of circulating tumor cells.
[0031] Use attached Figure 1 The cell filter and cell separator (CTCBIOPSY-A10, Wuhan Youzhiyou Medical Technology Co., Ltd.) were used to separate and enrich circulating tumor cells. The specific operations are as follows: ① Rinse the filter.
[0032] a) Open the upper and lower plugs of the filter and place the filter on the rinse rack; b) Use a Pasteur tube to add about 2 mL of 75% medical alcohol into the filter and wait for it to filter out naturally from the bottom of the filter; c) Add 4 mL of saline solution to the filter for rinsing to remove the residual alcohol in the filter and filter out the saline solution naturally; d) Repeat step c) twice, leaving an appropriate amount of saline to ensure that the filter membrane is moistened, and install the upper and lower plugs of the filter.
[0033] Note: If the alcohol does not filter out naturally or filters out too slowly during the filter rinsing process, discard the filter immediately.
[0034] ②Sample pretreatment.
[0035] Take 375 μL of 8% PFA (paraformaldehyde) and add it to a 15 ml centrifuge tube, add normal saline to 3 ml, take 5 ml of blood sample and add it to the aforementioned centrifuge tube, add normal saline to 15 ml, gently invert to mix, let stand at room temperature for 10 min to pre-fix the cells (process blood samples one by one).
[0036] ③Sample separation.
[0037] The sample separation process is semi-automatically completed by the cell separation instrument, as follows: a) Place the filter in the CTCBIOPSY-A10 cell separator; b) Remove the upper stopper and add about 8 mL of the fixed sample to the filter using a Pasteur tube. Click "Start". After the sample separation is complete, add the remaining 7 mL of sample to the filter using a Pasteur tube and click "Start" again to complete the sample separation. c) Add 4 mL of PBS to the filter tube and click "Start" to rinse the sample; d) Repeat step c) 2 more times.
[0038] (3) Perform Wright-Giemsa staining.
[0039] ① Methanol fixation: Add 500 μL methanol to the filter, fix at room temperature for 1 minute, and then click the "Start" button to run the device to drain all the methanol. If there is any methanol remaining, remove the filter from the machine, open the lower plug, and cover the upper plug to allow the remaining methanol to flow out naturally.
[0040] ②Take out the membrane and remove the cells on the back of the filter: stick the filter membrane to the bottom of the glass slide (if the filter membrane is relatively dry, add 5μL of methanol to the bottom of the glass slide and then stick the filter membrane so that the filter membrane is flat), and let the filter membrane dry naturally for 10 minutes.
[0041] ③ Paste the membrane: Add 5 μL of methanol to the middle part of the slide, stick the filter membrane with the front side facing up on the slide, try to stick the filter membrane as flat as possible, and let it dry naturally for 10 minutes.
[0042] ④ Draw a circle with a tissue pen: Use a tissue pen to draw a closed circle around the filter membrane that is slightly larger than the filter membrane and wait for 2 minutes to dry.
[0043] ⑤ Eosin staining: Add 100 μL of eosin stain solution onto the filter membrane, stain for 1 minute, then add 300 μL of PBS to dilute the eosin stain solution, and then discard the diluted stain solution.
[0044] ⑥ Methylene blue staining: Add 300μL of methylene blue staining solution, stain for 120s, and then discard the methylene blue staining solution.
[0045] ⑦ Rinse: Add deionized water and quickly pour out the residual liquid; repeat once to clean the residual methylene blue stain on the filter membrane to ensure that there is no obvious dye color residue on the filter membrane.
[0046] ⑧ Transfer to a new glass slide: Immediately peel off the stained filter membrane and transfer it to a new glass slide, making it as flat as possible. Dry it in a drying oven at 50℃ for 40 minutes before reading the slides.
[0047] ⑨ Sealing: After reading the slides, the slides can be sealed and stored. Add an appropriate amount of neutral resin sealing agent. After sealing, place the sealing agent in a drying oven (50℃, 30min) to accelerate the curing of the sealing agent. Be sure to avoid generating bubbles when sealing.
[0048] (4) Read the slides under a microscope according to the CTCs morphological identification criteria.
[0049] ① Take the mirror and place it.
[0050] a) Adjust the position of the microscope so that the microscope base is 3-4 cm away from the edge of the test bench, and install the eyepiece and objective lens; b) Turn on the power and adjust the brightness and aperture according to the objective lens magnification to make the light in the field of view uniform and of appropriate brightness.
[0051] ②Observation.
[0052] a) Place the prepared slide on the stage and press it with a slide clamp. The specimen should be facing the light hole. b) Rotate the rotator to place the 20x objective lens in the center of the light path, turn the coarse focus knob to raise the stage, carefully adjust the objective lens close to the specimen while looking from the side, then observe through the eyepiece, slowly lower the stage to bring the specimen into initial focus, and then adjust the fine focus knob to make the image clear; c) Slowly move the slide with the slide holder pusher, find the target cells in the 10x or 20x objective lens field of view, move to the center of the field of view, gently turn the 40x objective lens, and appropriately adjust the fine focus knob to make the image clear, observe and record. If the 40x field of view is still difficult to distinguish, turn the oil objective to the working position, add a drop of cedar oil to the sample area to be observed, slowly adjust the field of view to make it clear, observe and record.
[0053] Specifically, the morphological identification criteria for CTCs are as follows: i) Karyotype abnormalities, such as lobed or mulberry-shaped nuclei, can be compared with the morphology of surrounding blood cells as one of the criteria for determining whether a karyotype abnormality exists; ii) the nuclear-to-cytoplasmic ratio is greater than 0.8; iii) cell diameter (long end) greater than 15 μm; iv) The nucleus is darkly stained and unevenly stained, mainly because the tumor cells have increased chromatin and coarser granules; v) The nuclear membrane thickens and develops depressions or wrinkles, making the nuclear membrane irregular; vi) Presence of giant nucleoli or abnormal nuclear division.
[0054] If 4 or more of the above diagnostic criteria are met, it can be directly diagnosed as CTC; if giant nucleoli or abnormal nuclear division are present, and 2 of the other diagnostic criteria are met, it can also be diagnosed as CTC. If there are only giant nucleoli or abnormal nuclear division, or if 3 of the other diagnostic criteria are met, it can be diagnosed as a suspected CTC. When diagnosing CTC, it should be differentiated from necrotic cells or apoptotic cells. The difference is that although the nuclei of necrotic or apoptotic cells are stained darker, the nuclear membrane is destroyed, the structure is unclear, and there is no obvious nucleolus. A cell cluster composed of 3 or more CTCs gathered together is diagnosed as a circulating tumor microthrombus (CTM).
[0055] like Figure 2 Shown are microscopic images of a single CTC of lung cancer (a), a CTM of rectal adenocarcinoma (b), and a CTC of gastric cancer (c).
[0056] (5) Use laser microdissection to select cells.
[0057] Leica laser microdissection Leica LMD7 was used to perform cell dissection on CTCs or suspected CTCs identified in step (4) ( Figure 3 The specific steps are as follows: ① Computer startup: Turn on the computer associated with the microdissection instrument.
[0058] ② Turn on the microdissection instrument: Turn on the power switch on the back of the microdissection instrument chassis, turn the keyhole on the front of the chassis from "OFF" to "ON", and then turn on the green switch in the lower right corner.
[0059] ③Cutting operation: a) Open the "Leica laser Microdissection" control software on the computer and place the slide on the stage, face down; b) Click "Unload" on the upper toolbar to pop up the cell collection device, place the 0.2mL collection tube, and then confirm with "OK" in the pop-up box on the screen; c) Select the empty tube position "No Cap" in the lower left corner, click the sample plate "Specimen", select the low-power microscope 5x or 10x on the right, rotate the focus knob to find the target cell field of view, and then switch to the high-power microscope to focus and accurately locate the target cells; d) Select the collection tube position corresponding to the lower left corner of the screen, click "Ellipse" on the left toolbar, circle the target cell, select the corresponding target cell coordinates in the right recording box, click the green option "Start Cut" above the coordinates to cut, if the target cell does not fall off, click "Move Cut", circle the cut part, and make it fall off; e) Click "collector" on the toolbar above to observe and confirm that the cut cells have fallen into the collection tube; f) Click "Unload" on the upper toolbar to eject the collection tube, gently take it out, and tightly close the tube cap.
[0060] It is worth noting that laser positioning calibration is required before cell cutting: click "Calibrate" on the right side of the screen, select "YES" in the pop-up box, and click the mouse accordingly to coincide with the four "cross" cursors that appear on the screen. After the calibration is completed, click "OK" to confirm.
[0061] (6) Perform whole genome amplification on the selected cells.
[0062] Sample requirements: The starting amount of the sample is a trace amount of genomic DNA at the level of 0.5pg~1ng. To avoid exogenous DNA contamination, a Mg-free 2+ and Ca 2+Wash the cells with PBS solution. Make sure the volume of PBS solution does not exceed 2 μL in subsequent experiments.
[0063] Prepare control group DNA (5 μL): dilute the DNA storage solution to 30 pg / μL DNA with nuclease-free water, take 1 μL of the 30 pg / μL DNA solution, and add it to a PCR tube containing 4 μL of cell lysate as a positive control; take 1 μL of nuclease-free water and add it to a PCR tube containing 4 μL of cell lysate as a negative control.
[0064] Cell lysis: Prepare cell lysis mixture according to Table 1; collect target cells in a PCR tube containing 5 μL of cell lysis mixture (the volume of PBS solution containing target cell sample should not exceed 2 μL); incubate the sample in a preheated PCR instrument and set the reaction parameters for 1 cycle: 50℃, 50min; 80℃, 10min; 4℃, Forever.
[0065] Table 1
[0066] MALBAC pre-amplification: prepare the pre-amplification mixture according to Table 2; add 30 μL of the pre-amplification mixture to 5 μL of the cell lysate or the control group DNA sample; perform amplification in a PCR instrument, and the reaction conditions are as shown in Table 3.
[0067] Table 2
[0068] Table 3
[0069] Exponential amplification: prepare amplification mixture according to Table 4; add 30 μL of amplification mixture to 35 μL of pre-amplification product; perform amplification in a PCR instrument, and the reaction conditions are as shown in Table 5; the amplification product is stored in a -20°C refrigerator for subsequent experiments.
[0070] Table 4
[0071] Table 5
[0072] Product verification: The fragment length was detected by agarose gel electrophoresis. 5 μL of the amplified product was subjected to agarose gel electrophoresis (1% agarose gel, 110 V, 25-35 min). The size of the amplified product was 300-2000 bp.
[0073] (7) Use NGS technology to perform low-depth whole-genome sequencing of CTCs.
[0074] DNA sample detection: Qubit accurately quantifies DNA concentration, and DNA samples with a content of more than 0.5 μg are used to build the library.
[0075] Library construction: The genomic DNA was randomly broken into fragments of about 350 bp in length by Covaris fragmentor. After end repair and A-tailing, adapters were connected to both ends of the fragments to prepare the DNA library.
[0076] Library inspection: After the library is constructed, Qubit 2.0 is used for preliminary quantification, and then the insert size of the library is detected using Agilent 2100. After the insert size meets expectations, the effective concentration of the library (3 nM) is accurately quantified using the qPCR method to ensure the quality of the library.
[0077] Sequencing: If the library is qualified, the Illumina platform will be used for sequencing according to the effective concentration of the library and data output requirements.
[0078] (8) CNV analysis.
[0079] The original data from DNA sequencing is called raw data, which contains the sequence information of the sequencing sequence (reads) and its corresponding sequencing quality information. The format of the data is FSATQ (hereinafter referred to as fq), and every four lines of the file contain the information of a read (including sequence name, sequence, sequence ID, and sequencing quality of the sequence). Raw data will contain connector information, low-quality bases, and unmeasured bases (represented by N). This information will cause great interference to subsequent information analysis. These interfering information can be removed through sophisticated filtering methods to finally obtain valid data.
[0080] In this example, SOAPnuke software is used to filter the original offline data. The filtering criteria are as follows: ① Filter out reads containing adapter sequences; ② When the N content in a single-end sequencing read exceeds 5% of the read length, the read and the read that forms a paired-end pair with the read are filtered out; ③ When the number of low-quality (Q≤10, Q value is the quality score of each detected base) bases contained in a single-end sequencing read exceeds 20% of the length of the read, the read and the read that forms a paired-end pair with the read are filtered out.
[0081] Use bowtie2 to align reads to the human genome reference sequence GRCh38 (Genome Reference Consortium Human Build 38, also known as hg38), and then use samtools to count the number of reads covering each base, which is called coverage. After obtaining the coverage value of each base, the chromosome is divided into units of 200k length, called bins, and the average coverage value of all bases in each bin is counted.
[0082] The calculation formula of Z-score is as follows: First, the coverage value of each bin is normalized using formula (1), and then converted to Z-score using formula (2): ; ; Where: Coverage raw Coverage refers to the original coverage obtained by sequencing. controls, raw refers to the original coverage of the experimental control sample, V tumor refers to the normalized sequencing coverage of tumor samples, V control is the normalized sequencing coverage of the control sample.
[0083] Example 2 The method of Example 1 was used to detect and analyze CNVs in 4 single-cell samples (1 blood sample from a healthy individual, 1 H1975 cell line sample, 1 blood sample from a glioma patient, and 1 blood sample from a chest tumor patient). Figure 4 ) It can be seen that the CNV maps of healthy individuals are relatively neat, and the Z-score value is closer to 0; the CNV maps of cell lines and malignant tumors are uneven, with frequent gene fragment amplification (Gain) and deletion (Loss), which are significantly different from the maps of healthy individuals.
[0084] Example 3 Using the method of Example 1, 54 samples of different types were sequenced in this example, including 7 H1975 cell lines, 1 blood sample from a patient with colon adenocarcinoma (COAD), 5 blood samples from patients with gastric cancer (GC), 7 blood samples from patients with glioma, 14 blood samples from patients with lung cancer (LC), 4 blood samples from patients with thoracic cancer, 3 blood samples from patients with breast cancer (BC), and 13 blood samples from healthy individuals.
[0085] With the help of the binary classification algorithm of the R package "DNACopy", the genome is segmented according to the Z-score value to obtain the genome segments with significant changes. The same type of samples are grouped, and the Z-score values of all segments in each group are displayed in a box plot ( Figure 5 ). It can be seen that the Z-score values of healthy samples are more stable and concentrated, while the Z-score values of cell lines and malignant tumors are significantly higher, indicating that CNV events commonly occur in the genomes of cell lines and malignant tumor samples, and are significantly different from healthy individuals. This shows that single-cell genome CNV analysis has good potential for distinguishing benign and malignant cells and for early diagnosis of tumors.
[0086] In summary, the present invention first captures circulating tumor cells by physical properties, then uses Wright-Giemsa stain to stain the cells and identifies circulating tumor cells by cell morphology, and finally picks target cells by laser microdissection technology. The scheme can effectively enrich and obtain CTCs or suspected CTCs. At the same time, the scheme is compatible with subsequent whole genome sequencing and data analysis of target cells. Especially when combined with CNV analysis, the scheme of the present invention can be used to accurately distinguish between benign and malignant cells, which is of great significance for the early diagnosis of tumors.
[0087] It should be noted that the above embodiments are only part of the embodiments of the present invention rather than all the embodiments, and are only used to illustrate the technical solution of the present invention rather than to limit it. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
Claims
1. A whole genome data analysis method based on physics-based capture of circulating tumor cells, It is characterized in that The following steps are involved: S1. CTCBIOPSY system is used to separate circulating tumor cells in enriched blood samples based on cell physical properties, and target cells are picked based on cell morphology and by laser microdissection. S2, perform whole genome sequencing on target cells; S3. Analyze the sequencing data to obtain genetic variation information of target cells.
2. The whole genome data analysis method based on physics-based capture of circulating tumor cells according to claim 1, It is characterized in that In the CTCBIOPSY system, the pore size of the filter membrane used is 8 μm.
3. The whole genome data analysis method based on physics-based capture of circulating tumor cells according to claim 1, It is characterized in that Step S1 includes: S11, draw venous blood and use CTCBIOPSY system to separate and enrich circulating tumor cells; S12, taking out the filter membrane in the CTCBIOPSY system, and using Wright-Giemsa staining solution to stain cells and prepare slides; S13. Read the slides and select the target cells to be tested by laser microdissection according to the cell morphology, wherein the target cells are selected in accordance with at least one of the following criteria: ① abnormal karyotype; ② nuclear-cytoplasmic ratio greater than 0.8; ③ cell diameter greater than 15 μm; ④ darkly stained nuclei and unevenly stained; ⑤ thickened nuclear membrane with depressions or wrinkles, and irregular nuclear membrane; ⑥ giant nucleoli or abnormal nuclear division.
4. The whole genome data analysis method based on physics-based capture of circulating tumor cells according to claim 3, It is characterized in that If the target cell meets at least 4 conditions, it can be confirmed as a circulating tumor cell. If the target cell has condition ⑥ and meets the other two conditions at the same time, it can be confirmed as a circulating tumor cell. If the target cell only has condition ⑥ or meets any other three conditions, it can be confirmed as a suspected circulating tumor cell.
5. The whole genome data analysis method based on physics-based capture of circulating tumor cells according to claim 1, It is characterized in that Step S2 specifically includes: firstly using the MALBAC whole genome amplification kit to amplify the target cell genome, and then using the second-generation sequencing technology to perform low-depth whole genome sequencing.
6. The whole genome data analysis method for capturing circulating tumor cells based on physics according to claim 1, It is characterized in that Step S3 performs CNV analysis on the sequencing data.
7. The whole genome data analysis method based on physics-based capture of circulating tumor cells according to claim 6, It is characterized in that Step S3 specifically includes: S31, perform quality control on sequencing data; S32. Use bowtie2 to align the reads obtained after quality control with the reference genome, use samtools to calculate the base coverage value, distinguish different chromosomes and divide the bin units according to the length of 200k, calculate the average coverage value of the bin, calculate the Z-score value according to formulas (1) and (2), and then use the Z-score value to perform CNV map analysis; Among them, formula (1) and formula (2) are specifically as follows: , , In the formula, Coverage raw Coverage refers to the original coverage obtained by sequencing. controls, raw refers to the original coverage of the experimental control sample, V tumor refers to the normalized sequencing coverage of tumor samples, V control is the normalized sequencing coverage of the control sample.
8. The whole genome data analysis method based on physics-based capture of circulating tumor cells according to claim 7, It is characterized in that The quality control conditions in step S31 are: Filter out reads containing adapter sequences; When the number of undetected bases in a single-end sequencing read exceeds 5% of the length of the read, the read and the reads that form a paired-end pair with the read are filtered out; When the number of low-quality bases in a single-end sequencing read exceeds 20% of the length of the read, the read and the reads that form a paired-end pair with the read are filtered out.
9. The whole genome data analysis method based on physics-based capture of circulating tumor cells according to claim 7, It is characterized in that The reference genome in step S32 is the human genome reference sequence GRCh38.
10. The whole genome data analysis method for capturing circulating tumor cells based on physics according to claim 1, It is characterized in that The circulating tumor cells include circulating tumor cells from lung cancer, gastric cancer, colon adenocarcinoma, glioma and breast cancer.
Citation Information
Patent Citations
Novel circulating tumor cell identification technology
CN111812071A
Methods for characterization of circulating tumor cells
WO2023102513A2
